Paroxysmal nocturnal haemoglobinuria
PNH and new oral complement inhibitors.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 11, 22, 22, 30, 19.
All papers from the last 12 months
188 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapiesHematology2026 Dec 31PMID 42275288
- Case report: persistent anemia after eculizumab in paroxysmal nocturnal hemoglobinuria: non-dominantly active intravascular hemolysisHematology2026 Dec 31PMID 41860373
- Recurrent thoracic aortic stent graft thrombosisJ Vasc Surg Cases Innov Tech2026 DecPMID 42828113
- Terminal complement inhibition is associated with renal, hematologic, and thrombotic complications during septic shock: A global propensity score-matched cohort studyJ Crit Care2026 DecPMID 42526359
- Switching patients with PNH from pegcetacoplan to iptacopan: a case seriesHematology2026 DecPMID 41657019
- Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuriaHematology2026 DecPMID 41607343
- Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-makingJ Med Econ2026 DecPMID 41518611
- Real-world clinical outcomes and treatment response in complement inhibitor experienced and naïve PNH patients prescribed pegcetacoplan in Europe and CanadaHematology2026 DecPMID 41480918
- Complement targeting in autoimmune diseasesCurr Opin Hematol2026 Nov 1PMID 42710066Review
- Iptacopan combined with immunosuppressive therapy for aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case reportMedicine (Baltimore)2026 Oct 16PMID 42888561
More hematology trends
All specialties →Myelofibrosis treatment
JAK inhibitors and newer drugs in myelofibrosis.
Key point: Ruxolitinib-based combination regimens showed improved spleen and symptom responses with acceptable safety, with efficacy significantly influenced by prior JAK inhibitor exposure.
Post-transplant cyclophosphamide
Cyclophosphamide after stem cell transplant to prevent graft-versus-host disease.
Key point: Post-transplant cyclophosphamide appears to reduce graft-versus-host disease without increasing relapse or mortality in matched related donor transplantation for acute leukemia.
Haemophilia
Haemophilia and its newer treatments, including gene therapy and non-factor drugs.
Targeted therapy in CLL
BTK and BCL2 inhibitors in chronic lymphocytic leukaemia.
Key point: In CLL/SLL, treatment selection is tailored based on age, genetic risk and comorbidities, prioritizing zanubrutinib, acalabrutinib and venetoclax-based regimens.
Menin inhibitors in AML
Revumenib, ziftomenib and other menin inhibitors in acute leukaemia.
DOACs in heparin-induced thrombocytopenia
Studies of direct oral anticoagulants for the treatment of heparin-induced thrombocytopenia.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"paroxysmal nocturnal hemoglobinuria"[tiab] OR "paroxysmal nocturnal haemoglobinuria"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.